Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 8/20 | 0.40 |
| ▸ | DRD4 | P21917 | 8/20 | 0.40 |
| ▸ | DRD3 | P35462 | 8/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6580455 | 0.81 | CTSK (0.47) | GBA1FUCA1LARS1 | |
| Hydrochloric Acid SCHEMBL27483445 | 0.81 | CTSK (0.47) | GBA1FUCA1LARS1 | |
| SCHEMBL17152346 | 0.80 | NPFFR2 (0.60) | NPFFR2BCHEDRD2DRD4DRD3 | |
| SCHEMBL17152556 | 0.79 | DRD4 (0.50) | NPFFR2DRD2DRD4DRD3LMNA | |
| SCHEMBL17152426 | 0.79 | BCHE (0.56) | NPFFR2BCHEDRD2DRD4DRD3 | |
| SCHEMBL5026745 | 0.77 | ARG1 (0.41) | LARS1 | |
| SCHEMBL4450666 | 0.77 | ARG1 (0.41) | LARS1 | |
| SCHEMBL6580315 | 0.76 | UTS2R (0.54) | RAB9ASMN1; SMN2 | |
| SCHEMBL4689695 | 0.76 | ALDH1A1 (0.47) | BCHE | |
| SCHEMBL7425826 | 0.76 | ALDH1A1 (0.47) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-0936912-B1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-20020128476-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| EP-0936912-A4 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0936912-A1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998005336-A1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | CTSK, CTSZ, CTSS | NPFFR2 4073/4885GBA1 161/4885FUCA1 302/4885 |
| US-20020128476-A1 | Inhibitors of cysteine protease | CTRC, RCE1, CTRL | NPFFR2 2421/4885GBA1 1394/4885FUCA1 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.